The CB(1) Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability

BACKGROUND: Multiple studies suggest a pivotal role of the endocannabinoid system in regulating the reinforcing effects of various substances of abuse. Rimonabant, a CB(1) inverse agonist found to be effective for smoking cessation, was associated with an increased risk of anxiety and depression. He...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Neuropsychopharmacol
Main Authors: Gueye, Aliou B., Pryslawsky, Yaroslaw, Trigo, Jose M., Poulia, Nafsika, Delis, Foteini, Antoniou, Katerina, Loureiro, Michael, Laviolette, Steve R., Vemuri, Kiran, Makriyannis, Alexandros, Le Foll, Bernard
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Regular Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5203757/
https://ncbi.nlm.nih.gov/pubmed/27493155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyw068
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados